2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
5
Sarcoma
4
Neoplasms
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Cyclophosphamide
65
Peripheral Blood Stem Cell Transplantation
37
fludarabine phosphate
36
Doxorubicin
31
Etoposide
30
Vincristine
29
Whole-Body Irradiation
28
Rituximab
26
Prednisone
26
Brentuximab Vedotin
26
Mycophenolic Acid
25
Filgrastim
22
Cyclosporine
22
Methotrexate
20
Busulfan
19
Cytarabine
18
Radiotherapy
17
Antilymphocyte Serum
16
Tacrolimus
15
Melphalan
15
Carboplatin
14
Ifosfamide
13
Bortezomib
13
Methylprednisolone
12
Gemcitabine
11
Flow Cytometry
10
Lenalidomide
9
Dexamethasone
9
romidepsin
8
Vorinostat
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA